Search results
Piper Sandler keeps 'Overweight' on Allogene stock, highlights CAR-T potential By Investing.com
Investing.com· 2 days agoOn Monday, Piper Sandler reaffirmed its Overweight rating on Allogene Therapeutics (NASDAQ:ALLO)...
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL...
Morningstar· 5 days agoAmgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with ...
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Digital Journal· 1 day agoImmunotherapy, the latest technology in the war on cancer, can come in various forms; including: checkpoint inhibitors, Chimeric Antigen Receptor ("CAR") T-Cell< ...
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 2 days ago“The approval in the frontline consolidation phase, regardless of MRD status, allows us to reach...
Innovent Reports Oncology Pipeline Updates at Investor Meeting
Morningstar· 10 hours agoSAN FRANCISCO and SUZHOU, China, June 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Scientists Uncover Links Between MS and Epstein-Barr Virus
US News & World Report· 3 hours agoThe discovery that the Epstein-Barr virus might be a major driver of multiple sclerosis has re-energized research into the autoimmune disease. Now, investigators in the U.K. and Sweden believe ...
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 9.7% in May
ETF DAILY NEWS· 9 hours agoCaribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 11,510,000 ...
Age is just a number: Immune cell 'epigenetic clock' ticks independently of organism lifespan
Medical Xpress· 7 days agoScientists at St. Jude Children's Research Hospital and the University of Minnesota investigated the unique 'epigenetic clock' of T cell aging, demonstrating ...
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory...
Morningstar· 5 days agoPfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed ...
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias...
FOX40 Sacramento· 6 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
